Invivyd, Inc. (IVVD) announced on Tuesday that the first participant in its Phase 3 LIBERTY trial has been dosed with VYD2311, the company's investigational monoclonal antibody candidate for COVID-19. Company Profile
Invivyd is a commercial-stage biopharmaceutical company engaged in the development and commercialization of antibody therapies against viral infections. Invivyd's lead commercial product is Pemvidart, marketed as PEMGARDA, which is FDA-authorized under Emergency Use Authorization (EUA) for COVID-19.
VYD2311
VYD2311 is an investigational mAb candidate designed to neutralize contemporary virus lineages, especially SARS-CoV-2 (COVID-19).
This candidate has completed a Phase 1/2 trial and is currently in Phase 3, dubbed the DECLARATION trial, which assesses efficacy and safety in a broad population of participants to prevent symptomatic COVID. The U.S. FDA granted fast-track designation for VYD2311.
LIBERTY Trial
LIBERTY is a Phase 3, randomized, double-blind study to evaluate the safety, serum virus-neutralizing antibody responses, and pharmacokinetics of VYD2311, an mRNA COVID vaccine, and co-administration of VYD2311 with an mRNA COVID vaccine.
Additionally, it will explore the safety and immunology of co-administration of VYD2311 and the mRNA COVID-19 vaccine.
Total enrollment in the trial is expected to be approximately 210 participants aged between 18 and 49 years.
Patients will have randomized administration across three treatment arms:
- Intramuscular (IM) administration of a mRNA COVID-19 vaccine against placebo administered by IM injection- VYD2311 (250 mg) administered by IM injection and placebo administered by IM injection- VYD2311 (250 mg) administered by IM injection and an mRNA COVID-19 vaccine administered by IM injections.
The primary endpoint of the trial is safety based on treatment-emergent adverse events, injection site reactions, hypersensitivity reactions, and post-injection participants reporting more than 1 systemic symptom.
Further, the company added that, based on the study recruitment rate, it expects to report topline data from the LIBERTY trial in the third quarter of 2026.
Invivyd has traded between $0.4830 and $3.070 over the last year.
Invivyd shares closed Tuesday at $0.99, down 2.94%. In the pre-market, the shares are currently trading at $0.98, down 0.39%.
For more such biotech stock news, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.